NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

MLA

“NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (Aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19.” Plus Company Updates, 20 Aug. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.672798507&authtype=sso&custid=ns315887.

APA

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19. (2021, August 20). Plus Company Updates.

Chicago

Plus Company Updates. 2021. “NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (Aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19,” August 20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.672798507&authtype=sso&custid=ns315887.